Clinical trial
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
A Study Of PF-06463922 An ALK/​ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
ClinicalTrials.gov ID: NCT01970865
Sponsor: Pfizer
Information provided by: Pfizer (Responsible Party)
Last Update Posted: 2023-06-07
Brief Summary:
Phase 1 and 2 trial to study the safety, pharmacokinetics, pharmacodynamics, patient reported outcomes and efficacy of PF-06463922 in ALK + advanced non-small cell lung cancer patients and ROS1+ advanced non small cell lung cancer patients .
Official Title:
PHASE 1/2 STUDY OF PF-06463922 (AN ALK/ROS1 TYROSINE KINASE INHIBITOR) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING SPECIFIC MOLECULAR ALTERATIONS
Intervention / Treatment:
- Drug: PF-06463922
- Drug: Crizotinib
| Category | Value |
|---|---|
| Study Start (Actual) |
2014-01-08
|
| Primary Completion (Actual) |
2017-03-15
|
| Study Completion (Actual) |
2023-05-24
|
| Enrollment (Actual) | 334 |
| Study Type | Interventional |
| Phase | Phase 1 Phase 2 |
| Other Study ID Numbers |
B7461001
2013-002620-17 (EudraCT Number) |